Trials / Active Not Recruiting
Active Not RecruitingNCT05601323
A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic Cancer
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- SONIRE Therapeutics Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Suizenji | HIFU treatment |
| DRUG | Nal-IRI/FL | Nanoliposomal irinotecan, Fluorouracil, Levofolinate |
| DRUG | mFOLFIRINOX | Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin |
| DRUG | Gem/nab-PTX | Gemcitabine, nab-Paclitaxel |
Timeline
- Start date
- 2023-01-31
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
- First posted
- 2022-11-01
- Last updated
- 2026-03-16
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05601323. Inclusion in this directory is not an endorsement.